Colloidal gold kit and detection method for detecting insoluble proteins
The colloidal gold test kit, which uses specific antibody dilution and chromatography reaction, solves the problem of low binding efficiency in the detection of insoluble proteins, achieves rapid and accurate detection results, and is suitable for clinical applications.
Patent Information
- Application Number
- CN202510330339.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-20
- Publication Date
- 2025-09-30
- Estimated Expiration
- 2045-03-20
AI Technical Summary
When existing colloidal gold test kits are used to detect poorly soluble proteins, the poorly soluble proteins are difficult to dissolve and disperse evenly, resulting in low binding efficiency with colloidal gold-labeled antibodies, affecting detection sensitivity and accuracy.
Provided is a colloidal gold kit, including a test card, a centrifuge tube, and a pipette. Through specific antibody dilution and chromatography reaction, the color reaction of the test line area and the quality control line area is used to visually judge whether the target insoluble protein is present in the sample, thereby simplifying the operation process and reducing the professional skill requirements for the operator.
It achieves rapid and accurate detection of insoluble proteins, simplifies the detection process, improves the sensitivity and accuracy of detection, and is suitable for rapid clinical diagnosis.
Smart Images

Figure CN120121848B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of kits, and in particular to a colloidal gold kit and a detection method for detecting poorly soluble proteins. Background Art
[0002] Accurate detection of various proteins has always been a critical step in life science and medical research, as well as in clinical diagnostics. The detection of poorly soluble proteins, due to their unique physical and chemical properties, presents numerous unique challenges. Colloidal gold assays, as a commonly used detection tool, have continuously evolved to address these challenges, forming a series of systems with specific backgrounds and technical characteristics.
[0003] Poorly soluble proteins play a crucial role in many physiological and pathological processes. For example, in neurodegenerative diseases, the abnormal aggregation of β-amyloid and tau proteins, forming poorly soluble proteins, is a key factor in the development and progression of the disease. In cancer research, certain membrane or cytoskeletal-associated poorly soluble proteins are also closely associated with tumor invasion and metastasis. Therefore, accurate detection of poorly soluble proteins is crucial for early diagnosis, disease monitoring, and pathogenesis research. However, due to their highly folded, aggregated, or bound to other biomacromolecules, poorly soluble proteins have extremely low solubility under conventional detection conditions. This not only makes it difficult to effectively extract proteins from complex biological samples, but also prevents them from being evenly dispersed during the detection process, hindering their ability to fully interact with the detection reagents, severely impacting the sensitivity and accuracy of the assay. Traditional detection methods, such as enzyme-linked immunosorbent assays (ELISAs), often require cumbersome pretreatment steps to improve protein solubility, resulting in suboptimal detection efficiency and effectiveness.
[0004] Colloidal gold immunochromatography is a rapid diagnostic technique based on the antigen-antibody specific immune reaction. The basic principle is to label an antibody with colloidal gold. When a sample containing the target protein is added to the sample pad, the sample migrates along the chromatographic membrane under capillary action. During this migration, if the target protein is present in the sample, it first binds to the colloidal gold-labeled antibody to form a complex. When the complex moves to the test line (T line), it binds to another specific antibody immobilized on the T line, causing the colloidal gold to aggregate and develop color, thereby determining the presence of the target protein in the sample. The control line (C line) is used to verify that the detection process is proceeding normally.
[0005] However, when existing colloidal gold test kits are used to detect insoluble proteins, the insoluble proteins are difficult to dissolve and disperse evenly, resulting in low binding efficiency between them and colloidal gold-labeled antibodies, which affects the detection sensitivity and accuracy. Summary of the Invention
[0006] In order to solve the above technical problems, the present invention provides a colloidal gold kit and detection method for detecting insoluble proteins. The colloidal gold detection kit can intuitively judge whether the target insoluble protein is present in the sample by whether the detection line area and the quality control line area are colored, which is convenient for observation and analysis and is conducive to clinical application and promotion.
[0007] To this end, the present invention provides the following technical solutions:
[0008] In a first aspect, the present invention provides, in an optional embodiment, a colloidal gold kit for detecting poorly soluble proteins, comprising a test card, a swab, a No. 1 centrifuge tube, a No. 2 centrifuge tube, a No. 3 centrifuge tube, and a pipette;
[0009] The first centrifuge tube contains a specific antibody (i.e., primary antibody) against the target antigen in the test sample and a sample diluent, which is used to dilute the test sample that has been diluted once a second time and bind it to the target antigen in the test sample;
[0010] The second centrifuge tube contains a sample diluent for diluting the sample to be tested;
[0011] The third centrifuge tube is an empty tube and is used for adding the sample to be tested and for the first dilution;
[0012] The pipette is used to draw the sample diluent and the suspension after mixing it with the sample to be tested;
[0013] The test card includes a sample pad, a conjugate pad, a test pad, an absorbent pad and a base plate;
[0014] The lower surface of one end of the sample pad is in contact with the upper surface of one end of the conjugate pad, and the other end is in contact with the secondarily diluted sample in the first centrifuge tube. The lower surface of the other end of the conjugate pad is in contact with the upper surface of one end of the test pad, and the upper surface of the other end of the test pad is in contact with the lower surface of one end of the absorption pad.
[0015] Based on the direction from the binding pad to the absorption pad, a C1q area, a detection line area and a quality control line area are set on the test pad;
[0016] The bottom plate is arranged below the sample pad, the conjugate pad, the test pad and the absorption pad;
[0017] The conjugate pad contains colloidal gold-labeled secondary antibody against the target antigen antibody and colloidal gold-labeled quality control primary antibody, the C1q region contains complement C1q, the detection line region contains a tertiary antibody against the secondary antibody, and the quality control line region contains a quality control secondary antibody against the colloidal gold-labeled quality control primary antibody.
[0018] Preferably, the specific antibody against the target antigen in the test sample is a monoclonal mouse anti-human antibody specific for the target antigen. The colloidal gold-labeled secondary antibody against the target antigen antibody is a colloidal gold-labeled goat anti-mouse secondary antibody. The tertiary antibody against the secondary antibody is a rabbit anti-goat tertiary antibody. The colloidal gold-labeled quality control primary antibody is a colloidal gold-labeled mouse IgG antibody. The quality control secondary antibody against the colloidal gold-labeled quality control primary antibody is selected from a horse anti-mouse IgG antibody.
[0019] Preferably, the number of the specific antibodies against the target antigen in the sample to be tested is greater than the number of the insoluble proteins in the sample to be tested, and the remaining specific antibodies after binding with the insoluble proteins reach the conjugate pad from the sample pad and bind to the colloidal gold-labeled secondary antibody against the target antigen.
[0020] Preferably, the volume of the No. 1 centrifuge tube is 1.5 mL, the volume of the No. 2 centrifuge tube and the No. 3 centrifuge tube is 5 mL, the sample diluent is phosphate buffer, and the pipette is marked with a scale.
[0021] In a second aspect, the present invention provides, in an optional embodiment, a method for detecting poorly soluble proteins, comprising the following steps:
[0022] S1: Add 1 mL or 1 g of the sample to be tested into the third centrifuge tube, then use a pipette to draw 4 mL of sample diluent from the second centrifuge tube and add it to the third centrifuge tube. Pipet and evenly pipette to obtain the primary dilution solution.
[0023] S2: Add 0.5 mL of the primary dilution solution to a No. 1 centrifuge tube, mix thoroughly, and let stand for 15-30 minutes. Insert the other end of the sample pad of the test card that is exposed to the outside into the No. 1 centrifuge tube and allow it to fully contact with the solution to be tested. After waiting for 15 minutes, if the detection area of the test pad of the colloidal gold kit develops color, it means that the solution to be tested contains poorly soluble protein. If the detection area of the test pad of the colloidal gold kit does not develop color, it means that the solution to be tested does not contain poorly soluble protein.
[0024] The amount of the specific antibodies is greater than the amount of the insoluble proteins in the solution to be detected, and the amount of the specific antibodies is equal to the amount of the colloidal gold-labeled secondary antibodies on the conjugate pad of the colloidal gold kit.
[0025] Preferably, the insoluble protein includes but is not limited to normally existing keratin, collagen, elastin and one of pathologically related amyloid protein, ruxtin, huntingtin protein or α-synuclein.
[0026] Compared with the prior art, the present invention has one of the following beneficial effects:
[0027] 1. The colloidal gold detection kit provided by the present invention can intuitively judge whether the target insoluble protein is present in the sample by whether the detection line area and the quality control line area are colored, which is convenient for observation and analysis and is conducive to clinical application and promotion.
[0028] 2. The present invention is based on colloidal gold immunochromatography technology. After the sample is added, it can undergo rapid chromatography reaction under capillary action. No complex instruments or equipment are required, and the test results can be obtained in a short time, meeting the needs of clinical rapid diagnosis.
[0029] 3. The present invention does not require cumbersome pre-treatment to improve the solubility of poorly soluble proteins, simplifies the detection process, reduces the difficulty of operation, and has relatively low requirements on the professional skills of the operator.
[0030] 4. The present invention utilizes antigen-antibody specific immune reaction, combines colloidal gold labeling and immunochromatography principles, and overcomes the difficulty of detecting insoluble proteins to a certain extent, providing a new approach for their detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 Schematic diagram of the structure of the detection card in the colloidal gold kit of Example 1 and Example 2 of the present invention;
[0032] Figure 2 Schematic diagram of the distribution of the antigen in centrifuge tube No. 1 and the added K8 mouse anti-human primary antibody in case 1 of Example 2 of the present invention, and a schematic diagram of the distribution of each antibody on the detection card in the colloidal gold kit;
[0033] Figure 3 This is a schematic diagram of the distribution of the antibodies on the detection card in the colloidal gold test kit when the K8 mouse anti-human primary antibody that is not bound to the antigen in centrifuge tube No. 1 is chromatographed onto the sample pad in Case 1 of Example 2 of the present invention;
[0034] Figure 4 This is a schematic diagram of the distribution of various antibodies on the detection card in the colloidal gold test kit when the K8 mouse anti-human primary antibody chromatographed onto the sample pad is chromatographed onto the binding pad and combined with the gold-labeled goat anti-mouse secondary antibody in Example 2, Case 1 of the present invention;
[0035] Figure 5 This is a schematic diagram of the distribution of the antibodies on the test card in the colloidal gold test kit when the gold-labeled quality control primary antibody is chromatographed to the quality control line area and combined with the quality control secondary antibody in Example 2, Case 1 of the present invention;
[0036] Figure 6 Schematic diagram of the distribution of K8 mouse anti-human primary antibody added to centrifuge tube No. 1 in case 2 of Example 2 of the present invention and a schematic diagram of the distribution of various antibodies on the detection card in the colloidal gold kit;
[0037] Figure 7This is a schematic diagram of the distribution of various antibodies on the detection card in the colloidal gold test kit when the K8 mouse anti-human primary antibody in centrifuge tube No. 1 is chromatographed onto the sample pad in case 2 of Example 2 of the present invention;
[0038] Figure 8 This is a schematic diagram of the distribution of various antibodies on the detection card in the colloidal gold test kit when the K8 mouse anti-human primary antibody chromatographed onto the sample pad is chromatographed onto the binding pad and combined with the gold-labeled goat anti-mouse secondary antibody in the second case of Example 2 of the present invention;
[0039] Figure 9 This is a schematic diagram of the distribution of various antibodies on the detection card in the colloidal gold test kit when the gold-labeled quality control primary antibody is chromatographed to the quality control line area and combined with the quality control secondary antibody in the second case of Example 2 of the present invention. DETAILED DESCRIPTION
[0040] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0041] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.
[0042] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.
[0043] Example 1: This example provides a colloidal gold kit for detecting insoluble proteins, comprising a test card, a swab, a No. 1 centrifuge tube, a No. 2 centrifuge tube, a No. 3 centrifuge tube, and a pipette;
[0044] Centrifuge tube No. 1 contains a specific antibody (i.e., primary antibody) against the target antigen in the test sample and a sample diluent, which is used to dilute the test sample that has been diluted once a second time and to bind it to the target antigen in the test sample; centrifuge tube No. 2 contains a sample diluent, which is used to dilute the test sample; centrifuge tube No. 3 is an empty tube, which is used for adding the test sample and the first dilution; in this embodiment, the volume of centrifuge tube No. 1 is 1.5 mL, the volume of centrifuge tubes No. 2 and No. 3 is 5 mL, and the sample diluent is phosphate buffer.
[0045] The pipette is used to draw the sample diluent and the suspension after mixing it with the sample to be tested. In this embodiment, the pipette is provided with a scale.
[0046] See also Figure 1The test card includes a sample pad 1, a conjugation pad 2, a test pad 3, an absorption pad 4 and a bottom plate 5; the lower surface of one end of the sample pad 1 is in contact with the upper surface of one end of the conjugation pad 2, and the other end is in contact with the sample to be tested after secondary dilution in the No. 1 centrifuge tube, the lower surface of the other end of the conjugation pad 2 is in contact with the upper surface of one end of the test pad 3, and the upper surface of the other end of the test pad 3 is in contact with the lower surface of one end of the absorption pad 4; based on the direction from the conjugation pad 2 to the absorption pad 4, a C1q area 6, a detection line area 7 and a quality control line area 8 are provided on the test pad 3, and the bottom plate 5 is provided below the sample pad 1, the conjugation pad 2, the test pad 3 and the absorption pad 4; wherein, the conjugation pad 2 contains a colloidal gold-labeled secondary antibody against the target antigen antibody and a colloidal gold-labeled quality control primary antibody, the C1q area 6 contains complement C1q, the detection line area 7 contains a tertiary antibody against the secondary antibody, and the quality control line area 8 contains a quality control secondary antibody against the colloidal gold-labeled quality control primary antibody. In this embodiment, the specific antibody against the target antigen in the test sample is a monoclonal mouse anti-human antibody specific for the target antigen. The colloidal gold-labeled secondary antibody against the target antigen antibody is a colloidal gold-labeled goat anti-mouse secondary antibody. The tertiary antibody against the secondary antibody is a rabbit anti-goat tertiary antibody. The colloidal gold-labeled quality control primary antibody is a colloidal gold-labeled mouse IgG antibody. The quality control secondary antibody against the colloidal gold-labeled quality control primary antibody is selected from a horse anti-mouse IgG antibody. The insoluble protein is cytokeratin (K8 protein), an indicator of intestinal mucosal damage. The number of specific antibodies against the target antigen in the test sample is greater than the number of insoluble proteins in the test sample, and the remaining specific antibodies after binding to the insoluble proteins reach the conjugate pad from the sample pad and bind to the colloidal gold-labeled secondary antibody against the target antigen antibody.
[0047] Example 2: This example provides a method for detecting cytokeratin (K8 protein), an indicator of intestinal mucosal damage, which is divided into two cases:
[0048] In case 1, the solution to be tested contains K8 protein, and the detection method includes the following steps:
[0049] Prepare the colloidal gold kit (see Figure 1 );
[0050] Insert the other end of the sample pad of the colloidal gold kit into the No. 1 centrifuge tube containing the mixture of the sample to be tested and K8 mouse anti-human primary antibody (i.e., the specific antibody of K8 protein). The amount of K8 mouse anti-human primary antibody is greater than the amount of insoluble protein in the solution to be tested (see Figure 2 );
[0051] The K8 mouse anti-human primary antibody binds to the K8 protein in the test solution, and the excess K8 mouse anti-human primary antibody chromatographs into the sample pad (see Figure 3 );
[0052] The excess K8 mouse anti-human primary antibody in the sample pad flows into the binding pad and binds to the gold-labeled goat anti-mouse secondary antibody in the binding pad (see Figure 4 );
[0053] The conjugate of K8 mouse anti-human primary antibody and gold-labeled goat anti-mouse secondary antibody and the excess gold-labeled goat anti-mouse secondary antibody are chromatographed into the test pad and reach the C1q area on the test pad. The conjugate of K8 mouse anti-human primary antibody and gold-labeled goat anti-mouse secondary antibody binds to the C1q protein and is deposited on the C1q area. The excess gold-labeled goat anti-mouse secondary antibody continues to chromatograph into the detection line area of the test pad and binds to the rabbit anti-goat tertiary antibody. Then the detection line area will develop color (see Figure 5 ).
[0054] In case 2, the solution to be tested does not contain K8 protein, the detection method includes the following steps:
[0055] Prepare the colloidal gold kit (see Figure 1 );
[0056] Insert the other end of the sample pad of the colloidal gold kit into the No. 1 centrifuge tube containing the sample to be tested and the K8 mouse anti-human primary antibody mixture. The amount of K8 mouse anti-human primary antibody is greater than the amount of insoluble protein in the solution to be tested (see Figure 6 );
[0057] K8 mouse anti-human primary antibody was chromatographed onto the sample pad (see Figure 7 );
[0058] The K8 mouse anti-human primary antibody in the sample pad flows into the binding pad and binds to the gold-labeled goat anti-mouse secondary antibody in the binding pad (see Figure 8 );
[0059] The conjugate of K8 mouse anti-human primary antibody and gold-labeled goat anti-mouse secondary antibody flows through the test pad and reaches the C1q area on the test pad. The conjugate of K8 mouse anti-human primary antibody and gold-labeled goat anti-mouse secondary antibody binds to the C1q protein and is deposited on the C1q area. However, there is no excess gold-labeled goat anti-mouse secondary antibody in the conjugate pad and continues to flow through the test line area of the test pad. It cannot bind to the rabbit anti-goat tertiary antibody, so no color development occurs in the test line area (see Figure 9 ).
[0060] In both cases, the gold-labeled quality control primary antibody in the conjugate pad can enter the quality control line area through chromatography and bind to the quality control secondary antibody, causing the quality control line area to develop color.
[0061] Although the principles of the present invention have been described in detail above in conjunction with the preferred embodiments of the present invention, those skilled in the art should understand that the above embodiments are merely illustrative of the present invention and are not intended to limit the scope of the present invention. The details in the embodiments do not constitute a limitation on the scope of the present invention. Without departing from the spirit and scope of the present invention, any obvious changes such as equivalent transformations and simple substitutions based on the technical solution of the present invention fall within the scope of protection of the present invention.
Claims
1. A colloidal gold kit for detecting poorly soluble proteins, characterized in that: Includes test card, swab, No. 1 centrifuge tube, No. 2 centrifuge tube, No. 3 centrifuge tube and pipette; The first centrifuge tube contains a specific antibody against the target antigen in the sample to be tested and a sample diluent, which is used to dilute the sample to be tested once and bind it to the target antigen in the sample to be tested; The second centrifuge tube contains a sample diluent for diluting the sample to be tested; The third centrifuge tube is an empty tube and is used for adding the sample to be tested and for the first dilution; The pipette is used to draw the sample diluent and the suspension after mixing it with the sample to be tested; The test card includes a sample pad, a conjugate pad, a test pad, an absorbent pad and a base plate; The lower surface of one end of the sample pad is in contact with the upper surface of one end of the conjugate pad, and the other end is in contact with the secondarily diluted sample in the first centrifuge tube. The lower surface of the other end of the conjugate pad is in contact with the upper surface of one end of the test pad, and the upper surface of the other end of the test pad is in contact with the lower surface of one end of the absorption pad. Based on the direction from the binding pad to the absorption pad, a C1q area, a detection line area and a quality control line area are set on the test pad; The bottom plate is arranged below the sample pad, the conjugate pad, the test pad and the absorption pad; The conjugate pad contains colloidal gold-labeled secondary antibody against the target antigen antibody and colloidal gold-labeled quality control primary antibody, the C1q region contains complement C1q, the detection line region contains a tertiary antibody against the secondary antibody, and the quality control line region contains a quality control secondary antibody against the colloidal gold-labeled quality control primary antibody.
2. The colloidal gold kit for detecting poorly soluble proteins according to claim 1, characterized in that: The specific antibody against the target antigen in the sample to be tested is a monoclonal mouse anti-human antibody specific for the target antigen.
3. The colloidal gold kit for detecting poorly soluble proteins according to claim 1, wherein The colloidal gold-labeled secondary antibody against the target antigen antibody is a colloidal gold-labeled goat anti-mouse secondary antibody.
4. The colloidal gold kit for detecting poorly soluble proteins according to claim 1, wherein The tertiary antibody against the secondary antibody is a rabbit anti-goat tertiary antibody.
5. The colloidal gold kit for detecting poorly soluble proteins according to claim 1, characterized in that: The colloidal gold-labeled quality control primary antibody is a colloidal gold-labeled mouse IgG antibody.
6. The colloidal gold kit for detecting poorly soluble proteins according to claim 1, characterized in that: The quality control secondary antibody containing the quality control primary antibody labeled with colloidal gold is selected from horse anti-mouse IgG antibody.
7. The colloidal gold kit for detecting poorly soluble proteins according to claim 1, characterized in that: The number of the specific antibodies against the target antigen in the sample to be tested is greater than the number of the insoluble protein in the sample to be tested, and the remaining specific antibodies after binding with the insoluble protein reach the binding pad from the sample pad and bind to the colloidal gold-labeled secondary antibody against the target antigen.
8. The colloidal gold kit for detecting poorly soluble proteins according to claim 1, characterized in that: The volume of the No. 1 centrifuge tube is 1.5 mL, the volumes of the No. 2 and No. 3 centrifuge tubes are 5 mL, the sample diluent is phosphate buffer, and the pipette is marked with a scale.
9. A method for detecting insoluble proteins using the colloidal gold kit according to claim 1, characterized in that: The following steps are involved: S1: Add 1 mL or 1 g of the sample to be tested into the third centrifuge tube, then use a pipette to draw 4 mL of sample diluent from the second centrifuge tube and add it to the third centrifuge tube. Pipet and evenly pipette to obtain the primary dilution solution. S2: Add 0.5 mL of the primary dilution solution to a No. 1 centrifuge tube, mix thoroughly, and let stand for 15-30 minutes. Insert the other end of the sample pad of the test card that is exposed to the outside into the No. 1 centrifuge tube and allow it to fully contact with the solution to be tested. After waiting for 15 minutes, if the detection line area of the test pad of the colloidal gold kit is colored, it means that the solution to be tested contains poorly soluble protein. If the detection line area of the test pad of the colloidal gold kit is not colored, it means that the solution to be tested does not contain poorly soluble protein. The amount of the specific antibodies is greater than the amount of the insoluble proteins in the solution to be detected, and the amount of the specific antibodies is equal to the amount of the colloidal gold-labeled secondary antibodies on the conjugate pad of the colloidal gold kit.
10. The method for detecting poorly soluble proteins according to claim 9, wherein The insoluble protein includes keratin, collagen, elastin, and one of pathologically related amyloid protein, ruxtin, huntingtin protein or α-synuclein.
Citation Information
Patent Citations
Method for detecting tissue cell protein by using housekeeping protein
CN103048467A
Colloidal gold chromatography test strip for detecting skeletal muscle troponin I of cattle or sheep, and application thereof
CN109709339A
